SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

10 Aug 2022 Evaluate
Revenue reduced marginally to stand at Rs. 14692.80 millions during the quarter ended June 2022. The figure stood at Rs. 14786.00 millions during the year-ago period.Profit after Tax for the quarter ended June 2022 saw a decline of -49.49% from Rs. 2847.20 millions to Rs. 1438.20  millions.Operating profit for the quarter ended June 2022 decreased to 2762.60 millions as compared to 4075.90 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 14692.80 14786.00 -0.63 14692.80 14786.00 -0.63 53993.60 51391.60 5.06
Other Income 188.10 136.10 38.21 188.10 136.10 38.21 561.30 622.40 -9.82
PBIDT 2762.60 4075.90 -32.22 2762.60 4075.90 -32.22 12996.70 15758.20 -17.52
Interest 67.90 12.60 438.89 67.90 12.60 438.89 72.10 81.40 -11.43
PBDT 2694.70 4063.30 -33.68 2694.70 4063.30 -33.68 12924.60 15676.80 -17.56
Depreciation 534.10 499.60 6.91 534.10 499.60 6.91 2041.00 1877.20 8.73
PBT 2160.60 3563.70 -39.37 2160.60 3563.70 -39.37 10883.60 13799.60 -21.13
TAX 722.40 716.50 0.82 722.40 716.50 0.82 2174.20 2391.90 -9.10
Deferred Tax 127.90 91.50 39.78 127.90 91.50 39.78 201.40 -57.90 -447.84
PAT 1438.20 2847.20 -49.49 1438.20 2847.20 -49.49 8709.40 11407.70 -23.65
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 18.80 27.57 -31.79 18.80 27.57 -31.79 24.07 30.66 -21.50

Ipca Laboratories Share Price

1557.90 -5.80 (-0.37%)
07-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.30
Dr. Reddys Lab 1307.00
Cipla 1361.00
Zydus Lifesciences 940.10
Lupin 2460.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×